196 related articles for article (PubMed ID: 31190827)
41. A prospective, randomized, double blind, placebo-controlled evaluation of the effects of eicosapentaenoic acid and docosahexaenoic acid on the clinical signs and erythrocyte membrane polyunsaturated fatty acid concentrations in dogs with osteoarthritis.
Mehler SJ; May LR; King C; Harris WS; Shah Z
Prostaglandins Leukot Essent Fatty Acids; 2016 Jun; 109():1-7. PubMed ID: 27269707
[TBL] [Abstract][Full Text] [Related]
42. Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids.
Kidd PM
Altern Med Rev; 2007 Sep; 12(3):207-27. PubMed ID: 18072818
[TBL] [Abstract][Full Text] [Related]
43. Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story.
Singh S; Arora RR; Singh M; Khosla S
Am J Ther; 2016; 23(3):e905-10. PubMed ID: 25828517
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of Omega-3 and Korean Red Ginseng in Children with Subthreshold ADHD: A Double-Blind, Randomized, Placebo-Controlled Trial.
Lee J; Lee SI
J Atten Disord; 2021 Dec; 25(14):1977-1987. PubMed ID: 32847461
[TBL] [Abstract][Full Text] [Related]
45. Supplementation with high-dose docosahexaenoic acid increases the Omega-3 Index more than high-dose eicosapentaenoic acid.
Allaire J; Harris WS; Vors C; Charest A; Marin J; Jackson KH; Tchernof A; Couture P; Lamarche B
Prostaglandins Leukot Essent Fatty Acids; 2017 May; 120():8-14. PubMed ID: 28515020
[TBL] [Abstract][Full Text] [Related]
46. Eicosapentaenoic and docosahexaenoic acids-rich fish oil supplementation attenuates strength loss and limited joint range of motion after eccentric contractions: a randomized, double-blind, placebo-controlled, parallel-group trial.
Tsuchiya Y; Yanagimoto K; Nakazato K; Hayamizu K; Ochi E
Eur J Appl Physiol; 2016 Jun; 116(6):1179-88. PubMed ID: 27085996
[TBL] [Abstract][Full Text] [Related]
47. Omega-3 supplementation from pregnancy to postpartum to prevent depressive symptoms: a randomized placebo-controlled trial.
Vaz JDS; Farias DR; Adegboye ARA; Nardi AE; Kac G
BMC Pregnancy Childbirth; 2017 Jun; 17(1):180. PubMed ID: 28599630
[TBL] [Abstract][Full Text] [Related]
48. Effect of Omega-3 Fatty Acid Supplementation on Plasma Fibroblast Growth Factor 23 Levels in Post-Myocardial Infarction Patients with Chronic Kidney Disease: The Alpha Omega Trial.
de Borst MH; Baia LC; Hoogeveen EK; Giltay EJ; Navis G; Bakker SJL; Geleijnse JM; Kromhout D; Soedamah-Muthu SS
Nutrients; 2017 Nov; 9(11):. PubMed ID: 29137111
[TBL] [Abstract][Full Text] [Related]
49. Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: the influence of LCPUFA on neural development, aging, and neurodegeneration.
Janssen CI; Kiliaan AJ
Prog Lipid Res; 2014 Jan; 53():1-17. PubMed ID: 24334113
[TBL] [Abstract][Full Text] [Related]
50. Familial risk for bipolar I disorder is associated with erythrocyte omega-3 polyunsaturated fatty acid deficits in youth with attention-deficit hyperactivity disorder.
McNamara RK; Chen C; Tallman MJ; Schurdak JD; Patino LR; Blom TJ; DelBello MP
Psychiatry Res; 2022 Jul; 313():114587. PubMed ID: 35550258
[TBL] [Abstract][Full Text] [Related]
51. Docosahexaenoic acid for selective prevention of posttraumatic stress disorder among severely injured patients: a randomized, placebo-controlled trial.
Matsuoka Y; Nishi D; Hamazaki K; Yonemoto N; Matsumura K; Noguchi H; Hashimoto K; Hamazaki T
J Clin Psychiatry; 2015 Aug; 76(8):e1015-22. PubMed ID: 26335087
[TBL] [Abstract][Full Text] [Related]
52. Critical appraisal of omega-3 fatty acids in attention-deficit/hyperactivity disorder treatment.
Königs A; Kiliaan AJ
Neuropsychiatr Dis Treat; 2016; 12():1869-82. PubMed ID: 27555775
[TBL] [Abstract][Full Text] [Related]
53. Effect of Poly Unsaturated Fatty Acids Administration on Children with Attention Deficit Hyperactivity Disorder: A Randomized Controlled Trial.
Anand P; Sachdeva A
J Clin Diagn Res; 2016 Sep; 10(9):OC01-OC05. PubMed ID: 27790483
[TBL] [Abstract][Full Text] [Related]
54. Effects of 1-year treatment with highly purified omega-3 fatty acids on depression after myocardial infarction: results from the OMEGA trial.
Zimmer R; Riemer T; Rauch B; Schneider S; Schiele R; Gohlke H; Diller F; Steinbeck G; Katus H; Senges J;
J Clin Psychiatry; 2013 Nov; 74(11):e1037-45. PubMed ID: 24330904
[TBL] [Abstract][Full Text] [Related]
55. Nutrient supplementation with polyunsaturated fatty acids and micronutrients in rheumatoid arthritis: clinical and biochemical effects.
Remans PH; Sont JK; Wagenaar LW; Wouters-Wesseling W; Zuijderduin WM; Jongma A; Breedveld FC; Van Laar JM
Eur J Clin Nutr; 2004 Jun; 58(6):839-45. PubMed ID: 15164103
[TBL] [Abstract][Full Text] [Related]
56. The potential relevance of docosahexaenoic acid and eicosapentaenoic acid to the etiopathogenesis of childhood neuropsychiatric disorders.
Tesei A; Crippa A; Ceccarelli SB; Mauri M; Molteni M; Agostoni C; Nobile M
Eur Child Adolesc Psychiatry; 2017 Sep; 26(9):1011-1030. PubMed ID: 27988864
[TBL] [Abstract][Full Text] [Related]
57. Changes of Erythrocyte Fatty Acids after Supplementation with Highly Concentrated Docosahexaenoic Acid (DHA) in Pediatric Cystic Fibrosis: A Randomized Double-Blind Controlled Trial.
Ayats-Vidal R; Bosque-García M; Cordobilla B; Asensio-De la Cruz O; García-González M; Castro-Marrero J; López-Rico I; Domingo JC
J Clin Med; 2023 May; 12(11):. PubMed ID: 37297899
[TBL] [Abstract][Full Text] [Related]
58. Impulsiveness in children with attention-deficit/hyperactivity disorder after an 8-week intervention with the Mediterranean diet and/or omega-3 fatty acids: A randomised clinical trial.
San Mauro Martin I; Sanz Rojo S; González Cosano L; Conty de la Campa R; Garicano Vilar E; Blumenfeld Olivares JA
Neurologia (Engl Ed); 2022 Sep; 37(7):513-523. PubMed ID: 31883771
[TBL] [Abstract][Full Text] [Related]
59. Combined application of eicosapentaenoic acid and docosahexaenoic acid on depression in women: a meta-analysis of double-blind randomized controlled trials.
Yang JR; Han D; Qiao ZX; Tian X; Qi D; Qiu XH
Neuropsychiatr Dis Treat; 2015; 11():2055-61. PubMed ID: 26300645
[TBL] [Abstract][Full Text] [Related]
60. Circulating CD36+ microparticles are not altered by docosahexaenoic or eicosapentaenoic acid supplementation.
Phang M; Thorne RF; Alkhatatbeh MJ; Garg ML; Lincz LF
Nutr Metab Cardiovasc Dis; 2016 Mar; 26(3):254-60. PubMed ID: 26803595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
